Japan Approves Shionogi Allergy Drug For Helping Unborns Breathe
This article was originally published in PharmAsia News
Executive SummaryJapan's health ministry agreed to cover Shionogi's betamethasone under the nation's health-insurance system. The drug has been sold in Japan since the 1960s, but only for treatment of allergies. The newly approved indication is for unborn babies to help them breathe. The approval marks the first in Japan for a treatment aimed at the not-yet-born. Shionogi markets the drug in Japan as Rinderon. (Click here for more
You may also be interested in...
Brands unfairly maligned by powerful influencers, strictly on behalf of paying competitors, could have occasion to broach the subject with the US Federal Trade Commission, which seeks comment on its “Endorsement Guides” in an increasingly complex and competitive, digitized advertising environment.
At least one FTC commissioner seems convinced that the agency’s Enforcement Guides are ripe for an update to address unscrupulous influencer marketing practices. Democrat Rohit Chopra proposes their codification into formal rules that would make violators liable for civil penalties and damages under FTC Act provisions.
The US agency has suspended all routine surveillance inspections in China through the end of March because of coronavirus fears, commissioner Stephen Hahn announced late on 14 February. Despite expecting medical product shortages, Hahn said the agency is being proactive: “We are not waiting for drug and device manufacturers to report shortages to us” before acting. The timing of Hahn’s statement – at 6 p.m. EST on a Friday, at the beginning of a three-day US holiday weekend – suggests he isn’t particularly excited to share the information.